HHS Shields Three Ebola Vaccine Makers From Legal Liability
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline, NewLink Genetics and Johnson & Johnson gain protection for their candidate Ebola vaccines; NewLink teams up with Merck, and GSK prepares for Phase II/III studies in West Africa.
You may also be interested in...
Zika Vaccine Makers, 21st Century Cures Task Force Hit By Regulatory Freeze
HHS asked Federal Register Office to withdraw declaration providing liability immunity to Zika vaccine manufacturers and notice delegating authority under the Cures Act to refine the clinical trials data registry.
Regulatory Briefs: Ebola Trials Protocol, AstraZeneca Resubmits Iressa
FDA officials explain why randomized clinical trials of Ebola products are necessary and the Senate passes Ebola priority review voucher bill. Lilly/AstraZeneca start Alzeimer’s trial, Incyte gains new approval for Jakafi, Sunovion files for new use of Aptiom and AstraZeneca resubmits its once withdrawn lung cancer drug Iressa.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.